Status:
ACTIVE_NOT_RECRUITING
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
X-Linked Retinitis Pigmentosa
Eligibility:
All Genders
3+ years
Phase:
PHASE3
Brief Summary
A clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
Eligibility Criteria
Inclusion
- Male or female, 3 years of age or older, has XLRP confirmed by a retinal specialist and has a predicted disease-causing sequence variant in RPGR confirmed by an accredited laboratory.
Exclusion
- None
Key Trial Info
Start Date :
December 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 19 2029
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT04794101
Start Date
December 4 2020
End Date
December 19 2029
Last Update
December 5 2025
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Shiley Eye Institute Jacobs Retina Center
La Jolla, California, United States, 92093 0946
2
Childrens Hospital Los Angeles
Los Angeles, California, United States, 90027
3
Stanford Health Care
Palo Alto, California, United States, 94303
4
VitreoRetinal Associates, PA
Gainesville, Florida, United States, 32607